Corcept (CORT) CEO awarded 460,000 stock options in new grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

BELANOFF JOSEPH K reported acquisition or exercise transactions in this Form 4 filing.

Corcept Therapeutics reported that Chief Executive Officer Joseph K. Belanoff received a grant of stock options covering 460,000 shares on February 27, 2026. These options give him the right to buy company stock and are structured as long-term incentive compensation.

The options vest in equal installments on each monthly anniversary of February 27, 2026, over a four-year period, and each vesting installment is conditioned on his continued service through the applicable vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BELANOFF JOSEPH K

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	460,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 460,000 shares (Direct)

Footnotes (1)

[object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/03/2026 - 06:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BELANOFF JOSEPH K

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$35.7	02/27/2026		A		460,000		⁽¹⁾	02/27/2036	Common Stock	460,000	$0.00	460,000	D

Explanation of Responses:

1. Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff.	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Corcept Therapeutics (CORT) report for Joseph K. Belanoff?

Corcept Therapeutics reported that CEO Joseph K. Belanoff received a grant of stock options for 460,000 shares on February 27, 2026. The grant is a compensation award rather than an open-market stock purchase or sale.

How many stock options did the Corcept (CORT) CEO receive in this Form 4 filing?

The CEO received stock options covering 460,000 shares of Corcept Therapeutics common stock. This award is recorded as a derivative security grant and increases his directly held stock option position by the same amount reported in the filing.

When do Joseph K. Belanoff’s Corcept (CORT) stock options vest?

The options vest in equal installments on each monthly anniversary of February 27, 2026, over a four-year period. Each vesting installment requires Joseph K. Belanoff to remain in service through the relevant vesting date as specified.

Is the Corcept (CORT) CEO’s Form 4 transaction a stock purchase or a grant?

The transaction is a grant of stock options, not an open-market purchase. It is reported with transaction code “A,” described as a grant, award, or other acquisition of derivative securities for compensation purposes, rather than a buy on the public market.

What does transaction code “A” mean in the Corcept (CORT) CEO’s Form 4?

Transaction code “A” indicates a grant, award, or other acquisition of securities. In this case, it reflects a compensation grant of 460,000 stock options to the CEO, recorded as an acquisition of derivative securities rather than a market trade.

Does the Corcept (CORT) CEO’s option grant require continued service to vest?

Yes. The footnote explains that the options vest ratably in equal monthly installments over four years, starting February 27, 2026, and each installment is subject to the CEO’s continued service through the applicable vesting date.